ライフサイエンスコーパス: venom

1 fe-threatening anaphylaxis (e.g. Hymenoptera venom).

2 te anaphylaxis, predominantly to Hymenoptera venom.

3 pid venom, but not in those treated with bee venom.

4 o snakes and lizards, the fangs pre-date the venom.

5 h extremely severe anaphylaxis to paper wasp venom.

6 present as a toxic chemical defence in toad venom.

7 y of these scFvs and how they neutralize the venom.

8 indoors, unlike allergies to other types of venom.

9 th CS-alpha/beta motif described from animal venoms.

10 sue homeostasis and elimination of toxins or venoms.

11 can help to protect against the toxicity of venoms.

12 mechanisms in acquired host defense against venoms.

13 t frequent trigger (66%), followed by insect venom (19%).

14 ommon elicitor was drugs (41.1%) followed by venom (27.4%) and food (20.6%).

15 d smaller and necrotic xenogeneic GB; spider venom activated the innate immune system; venom increase

16 noparticles) has been assessed for antisnake venom activity and its potential to be used as an antido

17 gical processes within each stage, including venom, aggression, olfactory recognition as well as grow

18 strated in the short total synthesis of four venom alkaloids.

19 saliva-specific protein, named Aedes aegypti venom allergen-1 (AaVA-1), promotes dengue and Zika viru

20 Venom immunotherapy is indicated in venom-allergic children and adults to prevent further mo

21 found at a similar frequency in hymenoptera venom-allergic patients with and without elevated sBT le

22 gs can cause severe anaphylaxis in untreated venom-allergic patients.

23 ponses after stings varied in bee and vespid venom-allergic patients.

24 stic tool for risk assessment in Hymenoptera venom-allergic patients.

25 Diagnosis of Hymenoptera venom allergy (HVA) is straightforward in the majority o

26 mples (P </= .002) and control subjects with venom allergy (P < .0001).

27 01) and compared with those in patients with venom allergy and healthy control subjects (21 and 23.4

28 Vespid venom allergy and male sex likewise augment the risk of

29 , eczema, food allergy, rhinitis, urticaria, venom allergy and other probable allergic disorders) fro

30 blockers and/or ACE inhibitors in coexisting venom allergy are inconclusive and do not justify recomm

31 Hymenoptera venom allergy is a potentially life-threatening allergic

32 mptions, suggested that AIT for bee and wasp venom allergy is only likely to be cost-effective for ve

33 ) in patients with yellow jacket or Polistes venom allergy of two European geographical areas.

34 Hymenoptera venom allergy ranks among the top three causes of anaphy

35 We found one economic modelling study for venom allergy which, despite being based largely on expe

36 was conducted among 46 patients with Vespula venom allergy who had experienced severe HVA, 32 cMCD (2

37 ing VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had

38 In vespid venom allergy, cross-reactivity between venoms of differ

39 allergic rhinitis, asthma, food allergy and venom allergy, respectively.

40 tization and clinically relevant Hymenoptera venom allergy.

41 clinically relevant sensitization in vespid venom allergy.

42 lergic asthma, IgE-mediated food allergy and venom allergy.

43 nd safety of AIT in the management of insect venom allergy.

44 ithout asthma and in high-risk subgroups for venom allergy.

45 notherapy (AIT) for the management of insect venom allergy.

46 for differential sIgE diagnostics in vespid venom allergy.

47 ogous neofunctionalization occurred in snake venom alpha-neurotoxins upon loss of another pair of the

48 However, components of animal venoms also can sensitize individuals to develop severe

49 represent an increased risk for Hymenoptera venom anaphylaxis (HVA).

50 HalphaT was associated with grade IV venom anaphylaxis (relative risk = 2.0; P < .05) and mor

51 rizing the evolution of genes functioning in venom and nervous systems.

52 We screened fractions from several venoms and characterized a cystine knot toxin called JZT

53 ns associated with certain antigens, such as venoms and drugs.

54 tivated MCs detoxify an increasing number of venoms and endogenous toxins.

55 ladib was tested against several whole snake venoms and isolated PLA(2) toxins, demonstrating potent

56 ified the steroid bufalin (from Chinese toad venom) and the alkaloid lycorine (from Amaryllidaceae sp

57 provide insight into the regulation of snake venom, and broadly highlight the biological insight enab

58 iseases, food allergies, anaphylaxis, insect venom, and drug allergy.

59 Here, we investigate the evolution of fangs, venom, and mimetic relationships in reef fishes from the

60 parasitic worms, noxious substances, toxins, venoms, and environmental irritants but that also trigge

61 optera, including their genomes, morphology, venoms, and parasitoid and eusocial life styles.

62 munity serves to resist parasitic helminths, venoms, and toxins, but the role and regulation of neutr

63 found for grass and cat sensitization, while venom- and weed pollen-positive individuals were frequen

64 ate determinants (CCDs) in plants and insect venoms are a common cause of irrelevant positive test re

65 Spider venoms are a rich source of peptide modulators useful to

66 Most spider venoms are dominated by cysteine-rich peptides with a di

67 Snake venoms are important novel traits that are comprised of

68 Snake venoms are mixtures of toxins that vary extensively betw

69 Molecules from animal venoms are promising candidates for the development of n

70 Animal venoms are rich in hundreds of toxins with extraordinary

71 However, arthropod venoms are underexploited, although they are a rich sour

72 ls, including sprays, ointments and injected venoms, are another defence system used by animals.

73 Cohorts with systemic mastocytosis (SM) and venom as well as idiopathic anaphylaxis from referral ce

74 their complexity and the small quantities of venom available from most venomous species.

75 Yet, potency and the amount of venom available varies greatly across species, ranging f

76 Macrophages were activated in vitro by the venom, becoming more phagocytic; these results confirm t

77 10 In the periphery, an sPLA(2) found in bee venom (bee venom PLA(2)) administered with the incomplet

78 1), a peptide toxin isolated from cone snail venom, binds at the turrets of K(v)1.2 and targets a net

79 pable of broadly neutralizing distinct viper venom bioactivities in vitro by inhibiting different enz

80 Spider venom biomolecules induced smaller and necrotic xenogene

81 n (CTX), a peptide from the Leiurus scorpion venom, blocks voltage-gated K(+)-channels in a unique ex

82 was seen in all patients treated with vespid venom, but not in those treated with bee venom.

83 mmunoCAP system for routine diagnosis of bee venom (BV) allergy.

84 quences of inhibitory proteins purified from venoms by searching the sequences of the corresponding t

85 As with morphological weapons, venom can serve multiple purposes, including to facilita

86 ially a white, viscous liquid, the extracted venom colors within minutes under ambient conditions.

87 ics, and functional approaches to reveal one venom component, five neuropeptides with two different c

88 Thus, ShK-like1 is a toxic venom component.

89 ides with structural similarities to studied venom components and revealed their unexpected neuronal

90 obulins with the ability to neutralize snake venom components and to mitigate the progression of toxi

91 the genomic and evolutionary origins of most venom components are not understood.

92 ids in HBV, but also provided information on venom components from other metabolite classes (e.g., nu

93 eterogeneity in the expression of individual venom components is maintained in organoid cultures.

94 Venom components, such as peptide toxins, appear to have

95 Harvested venom peptides reflect crude venom composition and display biological activity.

96 ebite victims and we detail how variation in venom composition can result in treatment failure.

97 gs, but extensive interspecific variation in venom composition dictates that different antivenom trea

98 ogists to comprehensively characterize snake venom compositions, unravel the molecular mechanisms tha

99 results bring new insights for studies with venom compounds, PIs, and drug design.

100 Pain-producing animal venoms contain evolutionarily honed toxins that can be e

101 Some spider venoms contain thousands of unique peptides, but little

102 Venoms contain variable mixtures of bioactive proteins.

103 Naja sputatrix (Malayan spitting cobra) venom contains 15% secretory PLA2 of its dry weight.

104 We find that fangblenny venom contains a number of toxic components that have be

105 A typical Conus venom contains hundreds to thousands of bioactive peptid

106 C. atrox venom contains snake venom metalloproteinases that cleav

107 inging cells called nematocytes which fire a venom-covered barb via an unknown triggering mechanism.

108 evaluate preconditioning with Crotalus atrox venom (Cv-PC) as potential preventive therapy for reduci

109 on serves both as projectile and conduit for venom delivery.

110 affold, we engineered a library of over 1500 venom-derived peptides and identified JNJ63955918 as a p

111 ve the pharmacokinetics of existing or novel venom-derived peptides.

112 mes, support evolutionary studies and enable venom-driven drug discovery.

113 successfully neutralized the Daboia russelii venom (DRV) and Naja kaouthia venom (NKV)-induced lethal

114 , and these probably encode the minimal core venom effector proteins.

115 ed in allergic patients and beekeepers after venom exposure.

116 4-switched memory B cells expanded after bee venom exposure.

117 , including fatal anaphylaxis, on subsequent venom exposure.

118 noids and primary tissue identifies distinct venom-expressing cell types as well as proliferative cel

119 sensitization regimens require use of costly venom extracts and require frequent visits over extended

120 re pronounced in ImmunoCAP measurements with venom extracts than in sIgE analyses with recombinant an

121 complement C3 or its inactivation with Cobra Venom Factor (CVF) result in impaired muscle regeneratio

122 pletion of circulating complement with cobra venom factor eliminated, as expected, injury recorded at

123 in E8.5 Cmas-/- mice upon injection of cobra venom factor, resulting in exhaustion of the maternal co

124 Although rare, several taxa use venom for agonistic intraspecific competition (e.g. ghos

125 characterization of the clotting activity of venom from Daboia russelii, distinguishing it from the b

126 function space provides an impetus to screen venom from other Conus species for similar, short bioact

127 espladib prevents murine lethality caused by venom from the most medically-important vipers of Africa

128 Here, we perform an in vitro screen of venoms from 18 cone snail species to identify toxins tar

129 ression in the venom gland, recent losses of venom function occur primarily among genes that show bro

130 ucture guides precise expression of multiple venom gene families.

131 d gene expression data, we find evidence for venom gene-specific chromatin contact domains and identi

132 While the majority of venom genes have specialized expression in the venom gla

133 ind that a common mode of acquisition of new venom genes in parasitoid wasps is co-option of single-c

134 Here we use the rapid turnover of venom genes in parasitoid wasps to study how new gene fu

135 Loss of venom genes is primarily due to downregulation of expres

136 quencing reveal that recruitment and loss of venom genes occur primarily by rapid cis-regulatory expr

137 Snake microchromosomes are also enriched for venom genes, which we show have evolved through multiple

138 isplayed distinct expression patterns in the venom gland and this was confirmed by quantitative real-

139 duction and to highlight key distinctions of venom gland cellular and physiological function.

140 gene expression analyses of the rattlesnake venom gland in comparison with several non-venom tissues

141 such as the physiology and regulation of the venom gland itself, remain virtually unstudied.

142 kely mechanisms driving acidification of the venom gland lumen during venom production and storage.

143 oxvirus (DlEPV), a poxvirus found within the venom gland of Diachasmimorpha longicaudata wasps.

144 Here, we establish long-term expanding venom gland organoids from several snake species.

145 r and secretory activity in the steady state venom gland relative to other secretory tissues and iden

146 nom genes have specialized expression in the venom gland, recent losses of venom function occur prima

147 ctivation of stress response pathways in the venom gland, suggesting that mitigation of cellular stre

148 Further, we find evidence for venom gland-specific transcription factor activity and c

149 ractable model system representing the snake venom gland.

150 d cis-regulatory expression evolution in the venom gland.

151 Here, by profiling venom-gland transcriptomes of 10 funnel-web species, we

152 3,248 predicted protein-coding genes, 12,346 venom-gland-expressed genes constitute the 'venom-ome' a

153 enom-ome-specific toxins' (VSTs) that showed venom-gland-specific expression, and these probably enco

154 liced spidroin, a spidroin expressed only in venom glands, evolutionary mechanisms for spidroin diver

155 Although venom has evolved independently numerous times in animal

156 The evolution of fangblenny venom has seemingly led to phenotypic convergence via th

157 Spiked virus-like particles (VLPs) in wasp venom have clearly been linked to wasps' successful para

158 Peptides from cone snail venoms have served as invaluable molecules to target key

159 Honeybee (Apis mellifera) venom (HBV) has been a subject of extensive proteomics r

160 evaluate the safety and efficacy of honeybee venom immunotherapy (HBVIT) combined with Advax adjuvant

161 in volume and in quality, but suggested that venom immunotherapy (VIT) could substantially reduce the

162 A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist.

163 Lifelong venom immunotherapy (VIT) is recommended; however, its e

164 Venom immunotherapy (VIT) is safe, highly effective, and

165 Venom immunotherapy (VIT) was administered monthly for 3

166 d Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on A

167 Venom immunotherapy is also recommended in adults with o

168 Venom immunotherapy is indicated in venom-allergic child

169 ary, as well as adrenaline auto-injector and venom immunotherapy prescription.

170 ver general considerations before initiating venom immunotherapy, evidence-based clinical recommendat

171 vidence-based recommendations for the use of venom immunotherapy, has been informed by a formal syste

172 therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued.

173 The observed B-cell responses in both venom immunotherapy-treated patients and naturally expos

174 aims to give practical advice on performing venom immunotherapy.

175 prevent further systemic sting reactions is venom immunotherapy.

176 actors and thus reinforce the indication for venom immunotherapy.

177 eveals the evolutionary origins of fangs and venom in the Nemophini blennies and shows that, in contr

178 er venom activated the innate immune system; venom increased blood monocytes and the migration of mac

179 The venom increased monocytes, neutrophils and NK cells, and

180 coreceptor, and they explain how some snake venoms induce SIRS-like conditions.

181 Viper venom induced haemorrhagic, coagulant and anticoagulant

182 The venom induced pathophysiological response to sterile inf

183 Venom-induced anaphylaxis (VIA) is a common, potentially

184 dentifies SM among patients with hymenoptera venom-induced anaphylaxis in whom the diagnosis would mo

185 rteen SM patients presented with Hymenoptera venom-induced anaphylaxis, no skin lesions, and baseline

186 t NAC (N-acetyl cysteine) prevented B. atrox venom-induced necrosis.

187 h does not provide enough protection against venom-induced pathophysiological changes like haemorrhag

188 The cobra and viper venoms-induced sterile inflammatory molecules (IL-6, HMG

189 ne snail Conus geographus uses a specialized venom insulin to induce hypoglycemic shock in its prey.

190 We recently showed that this venom insulin, Con-Ins G1, has unique characteristics re

191 When tested in zebrafish and mice, venom insulins significantly lower blood glucose in the

192 e a rational design strategy for repurposing venoms into promising antimicrobials.

193 javanicus), we provide strong evidence that venom is used differentially by both sexes to defend ter

194 Snake venom is well known for its ability to incapacitate and

195 Snake venom L-amino acid oxidases (LAAOs) are flavoproteins, w

196 Characterization of teratocyte-secreted venom-like protein 8 (TSVP-8) indicated it inhibits mela

197 pite the extensive body of research on snake venom, many facets of snake venom systems, such as the p

198 ification of one prominent family, the snake venom metalloproteinases (SVMPs) that play key roles in

199 actions of C. atrox venom suggest that snake venom metalloproteinases are largely responsible for the

200 d inhibits the proteolytic activity of snake venom metalloproteinases from five clinically relevant s

201 C. atrox venom contains snake venom metalloproteinases that cleave fibrinogen into fib

202 Studies in progress are selecting the venom molecules with antitumor and immunomodulatory effe

203 Spider venom neurotoxins and cytolytic peptides are expressed a

204 M protease, essential for maturing of spider venom neurotoxins.

205 aboia russelii venom (DRV) and Naja kaouthia venom (NKV)-induced lethal activity.

206 tn), a cathelicidin-related peptide from the venom of a South American rattlesnake, possesses potent

207 onopeptide of only four amino acids from the venom of Conus textile that strongly potentiated current

208 Conopeptides are neurotoxic peptides in the venom of marine cone snails and have broad therapeutic p

209 uced currents of TRPA1 was isolated from the venom of sea anemone Metridium senile.

210 a cystine knot toxin called JZTx-27 from the venom of tarantula Chilobrachys jingzhao as a high-affin

211 ch (ACR) Periplaneta australasiae and in the venom of the honey bee Apis mellifera (HBV).

212 The venom of the marine predatory cone snails (genus Conus)

213 ing ammodytoxin (Atx), the beta-ntx from the venom of the nose-horned viper (Vipera a.

214 o 1,4-benzoquinone derivatives, found in the venom of the scorpion Diplocentrus melici following expo

215 ath, a cathelicidin peptide derived from the venom of the sea snake, Hydrophis cyanocyntus, using in

216 toxin precursor processing protease from the venom of the spider Cupiennius salei The chymotrypsin-li

217 oxic peptide derived from lycosin-I from the venom of the spider Lycosa singoriensis.

218 revious in vitro studies have shown that the venom of the spider Phoneutria nigriventer (PnV) is a po

219 eptide, mu-theraphotoxin-Pn3a, isolated from venom of the tarantula Pamphobeteus nigricolor, potently

220 the toxic active principle derived from the venom of the wasp Vespula lewisii, into synthetic antimi

221 lfide peptides Czon1107 and Cca1669 from the venoms of Conus zonatus and Conus caracteristicus, respe

222 spid venom allergy, cross-reactivity between venoms of different species can be a diagnostic challeng

223 venom-gland-expressed genes constitute the 'venom-ome' and this included 139 genes from 33 toxin fam

224 Among the 139 toxin genes were 19 'venom-ome-specific toxins' (VSTs) that showed venom-glan

225 ing WAO diagnostic criteria) to drugs, food, venom or spontaneous anaphylaxis, recruited using purpos

226 significantly reduced itching caused by wasp venom peptide degranulation of mast cells in mice by 51%

227 the first crystal structure of an ICK spider venom peptide not bound to a substrate.

228 s, to an analogue of huwentoxin-IV, a spider-venom peptide that allosterically modulates channel gati

229 Venom peptide toxins such as conotoxins play a critical

230 monstrate that Hi1a, a disulfide-rich spider venom peptide, is highly neuroprotective in a focal mode

231 Using the tarantula venom-peptide ProTX-II as a scaffold, we engineered a li

232 nnel-web spider produces 33 superfamilies of venom peptides and proteins.

233 Venom peptides are promising drug leads, but their thera

234 using human fatalities, which are induced by venom peptides known as delta-hexatoxins (delta-HXTXs).

235 Harvested venom peptides reflect crude venom composition and displ

236 ng phosphodiesterase activity, such as snake venom phosphodiesterase, mammalian ectonucleotide pyroph

237 rporation increases resistance against snake venom phosphodiesterase.

238 ospholipid as a novel substrate of honey bee venom phospholipase A2.

239 In this study, we demonstrate that both bee venom PLA(2) and murine sPLA(2)-X have adjuvant activity

240 eriphery, an sPLA(2) found in bee venom (bee venom PLA(2)) administered with the incomplete Ag OVA le

241 reening of the Phoneutria nigriventer spider venom (PnV) antitumor effects by our group has shown tha

242 e analysis of 102 species we show that snake venom potency is generally prey-specific.

243 f atypical prey species as models to measure venom potency.

244 Huwentoxin-IV, a component of tarantula venom, potently blocks sodium channels and is an attract

245 We investigated if Naja sputatrix venom preconditioning (VPC) reduces surgical brain injur

246 and packaged into nematocysts, the cnidarian venom-producing stinging capsules.

247 terize a complement of mechanisms underlying venom production and regulation.

248 cidification of the venom gland lumen during venom production and storage.

249 gical and cellular processes associated with venom production and to highlight key distinctions of ve

250 tion, development of axis pattern formation, venom production, haplo-diploid sex determination, and h

251 of cellular stress is a crucial component of venom production.

252 s is co-option of single-copy genes from non-venom progenitors.

253 ng their specific physiological functions as venom proteins in suppressing host immune responses.

254 ese are knottins that contribute >90% of the venom proteome.

255 nstrates that bioactive molecules present in venoms provide essential pharmacological tools that syst

256 Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately

257 Synthetic venom reconstituted through recombinant VST expression w

258 stigated whether the changes observed during venom-related anaphylaxis also occur during allergic rea

259 s most common in children aged 0 to 9 years, venom-related anaphylaxis was most common in those 20 to

260 Venoms represent previously untapped sources of novel dr

261 actives from mixtures of standards and snake venoms, revealing active peptides and coagulopathic prot

262 28-kDa heterodimer with optimum activity at venom's pH of 6.0.

263 deep anterior grooves and their coupling to venom secretory tissue provide Meiacanthus spp. with tox

264 umor effects by our group has shown that the venom significantly affected glioblastoma cell lines.

265 en independently recruited into other animal venoms, some of which cause toxicity via interactions wi

266 The venom-specific IgG4 concentrations increased during VIT

267 naphylaxis deaths, the most common cause was venom-stinging insect (51.4%).

268 Naja sputatrix venom sublethal dose was injected subcutaneously for 3 c

269 contain a high diversity of toxins in their venom such as conotoxins, which are short polypeptides s

270 Cv-PC studies with fractions of C. atrox venom suggest that snake venom metalloproteinases are la

271 and an evolutionary pathway from nervous to venom system in Cnidaria.

272 in recruitment from the cnidarian nervous to venom system.

273 Venom systems have evolved on multiple occasions across

274 esearch on snake venom, many facets of snake venom systems, such as the physiology and regulation of

275 We identified a peptide from green mamba venom that exhibits nanomolar affinity for the V2R witho

276 y tissue provide Meiacanthus spp. with toxic venom that they effectively employ for defense.

277 ribe a family of small proteins in centipede venoms that inhibit the pore (hKir6.2) of a human ATP-se

278 e venom gland in comparison with several non-venom tissues to characterize physiological and cellular

279 lergen-specific B cells before and after bee venom tolerance induction.

280 ogical processes, including immune defenses, venom toxicity, and sperm maturation.

281 between Varespladib and a PLA(2)-like snake venom toxin (MjTX-II).

282 ization of 191 species and identified 20,206 venom toxin sequences.

283 MT7, a subtype-selective anti-M(1)AChR snake venom toxin.

284 New work shows that parasitoid wasp venom toxins evolve by the co-option of genes rather tha

285 y based on inhibitory molecules for specific venom toxins have gained renewed interest.

286 n antivenom antibodies and epitopes on snake venom toxins, a high-throughput immuno-profiling study o

287 Spider venom toxins, such as Protoxin-II (ProTx-II), have recen

288 peptides, adapted to the maturing of spider venom toxins.

289 olecular mechanisms underlying T. serrulatus venom (TsV) activity remain unknown.

290 herapeutic approaches designed to circumvent venom variation and deliver next-generation treatments f

291 ravel the molecular mechanisms that underpin venom variation, and elucidate the ensuing functional co

292 The effect of venom was also evaluated on macrophages in vitro.

293 psin inhibitor from Tityus obscurus scorpion venom was characterized and named ToPI1, with 33 amino a

294 The venom was effective at impairing tumor development in mu

295 se compounds were isolated from the scorpion venom, we developed laboratory syntheses from commercial

296 ttin, the active molecule of apitoxin or bee venom, were investigated on human red blood cells (RBCs)

297 hesis was that preconditioning with C. atrox venom will produce fibrinogen spilt products, thereby up

298 onomeric, insulin-like peptide in cone-snail venom with moderate human insulin-like bioactivity.

299 notoxins RgIA and GeXIVA from marine mollusk venom, with an arginine content of >30%.

300 who may be exposed to multiple exposures to venom/year (eg bee keepers).

301 We also show that venom yields are lower in species occupying three dimens